FTY720 in multiple sclerosis: the emerging evidence of its therapeutic value

摘要: INTRODUCTION: Multiple sclerosis is a demyelinating disease of the central nervous system which can cause severe disability and has profound effects on patients' quality life over several decades. Although there no cure for disease, recently developed disease-modifying agents have modest impact progression. There therefore need new, effective, well-tolerated treatment multiple FTY720 (an orally administered immunomodulatory compound with novel mechanism action) one number being evaluated this disease. AIMS: The objective article to assess therapeutic potential FTY720, now in phase II clinical trials, through review published evidence. EMERGING EVIDENCE: good evidence that achieves immunomodulation as shown by reversible redistribution peripheral blood lymphocytes after oral administration. Two meeting abstracts been showing results obtained 12-month trial patients active relapsing sclerosis. significantly improves both patient-oriented (relapse rate) disease-oriented outcomes (inflammatory activity). well tolerated. PROFILE: Based these early from development program, be an effective agent Further ongoing multinational III studies are awaited.